Valuation: Structure Therapeutics Inc.

Market Cap 1.24B 1.13B 1.05B 946M 1.78B 116B 1.85B 12.66B 5B 62.69B 4.66B 4.56B 198B P/E 2026 *
-7.87x
P/E 2027 * -6.37x
Enterprise Value 566M 516M 477M 431M 811M 52.89B 843M 5.76B 2.28B 28.55B 2.12B 2.08B 90.15B EV / Sales 2026 *
-
EV / Sales 2027 * 16,771x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day-4.46%
1 week-17.14%
Current month-20.62%
1 month-17.65%
3 months-67.57%
6 months-51.92%
Current year-75.04%
1 week 17.34
Extreme 17.34
20.5
1 month 17.34
Extreme 17.34
23.83
Current year 17.34
Extreme 17.34
94.77
1 year 17.34
Extreme 17.34
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 30/04/2022
Chief Executive Officer 62 30/04/2019
Chief Operating Officer 49 14/04/2026
Director TitleAgeSince
Director/Board Member 62 31/01/2019
Chairman 68 18/01/2022
Director/Board Member 66 28/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Conversion

Chief Technology Officer

-20,040 0.0143%
01/09/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
-4.46%-17.14%-49.68%-67.71% 1.3B
-1.34%-3.09%+56.10%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.01% 58.86B
+0.54%+0.45%+25.96%+87.77% 55.22B
-2.34%-3.90%+10.90%+115.97% 47.21B
+0.09%-6.08%+18.67%+25.90% 42.45B
-2.58%+0.24%+18.54%+41.28% 36.44B
-1.76%-11.56%+126.44%+649.27% 35.19B
-0.17%-1.83%+82.46%+57.69% 32.66B
-1.69%-0.79%-40.58%+382.68% 26.73B
Average -1.31%-5.25%+25.78%+145.17% 40B
Weighted average by Cap. -0.85%-3.69%+33.95%+143.29%

Financials

2026 *2027 *
Net sales - 45.45K 41.45K 38.32K 34.59K 65.14K 4.25M 67.71K 463K 183K 2.29M 171K 167K 7.24M
Net income -479M -437M -404M -365M -687M -44.8B -714M -4.88B -1.93B -24.18B -1.8B -1.76B -76.36B -586M -534M -494M -446M -840M -54.75B -873M -5.97B -2.36B -29.55B -2.2B -2.15B -93.31B
Net Debt -677M -617M -571M -515M -970M -63.24B -1.01B -6.89B -2.72B -34.14B -2.54B -2.49B -108B -481M -438M -405M -366M -689M -44.91B -716M -4.89B -1.93B -24.24B -1.8B -1.77B -76.54B
Projected Income Statement - Annual - Structure Therapeutics Inc.
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
18/11/26 US$17.36 -4.46% 1,100,440
17/11/26 US$18.17 -2.15% 583,686
16/11/26 US$18.57 -7.15% 762,992
13/11/26 US$20.00 +0.81% 1,346,425
12/11/26 US$19.84 -5.30% 1,038,141
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Structure Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
17.36USD
Average target price
104.86USD
Spread / Average Target
+504.02%
  1. Stock Market
  2. Stocks
  3. GPCR Stock